In our previous study, we found that the AXL/AKT pathway promotes BRAF inhibitor resistance in melanoma with wild-type PTEN, but not in melanoma with impaired PTEN26, indicating that PTEN status affects the molecular route to resistance to BRAF inhibition in melanoma27. The gene discussed is BRAF; the disease is melanoma.